Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

Trial Profile

A Single-Arm, Single Sequence, Multiple Ascending Dose Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 2004 (Primary)
  • Indications Pervasive child development disorders
  • Focus Adverse reactions
  • Sponsors Axial Biotherapeutics
  • Most Recent Events

    • 27 Nov 2019 Planned number of patients changed from 25 to 35.
    • 18 Nov 2019 According to an Axial Biotherapeutics media release, topline data from this trial anticipated in 2020.
    • 18 Nov 2019 Status changed from recruiting to active, no longer recruiting, as reported in an Axial Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top